High serum YKL-40 level in patients with COPD is related to hypoxemia and disease severity

Tohoku Journal of Experimental Medicine

Volumn 229, Issue 2, 2013, Pages 163-170

  Gumus, Aziz ^a   Kayhan, Servet ^a   Cinarka, Halit ^a   Kirbas, Aynur ^a   Bulmus, Necati ^a   Yavuz, Asiye ^a   Sahin, Unal ^a   Ozkaya, Sevket ^b  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^b MEDICAL PARK HOSPITAL   (Turkey)

Author keywords

Chitin binding glycoprotein; Chronic obstructive pulmonary disease; Hypoxemia; Inflammation; Saturation

Indexed keywords

GLYCOPROTEIN; HEMOGLOBIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; AGE; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; BODY MASS; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPOXEMIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OXYGEN DESATURATION; PATHOGENESIS; PH; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE;

ADIPOKINES; ANOXIA; CASE-CONTROL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LECTINS; MALE; MIDDLE AGED; OXYGEN; PARTIAL PRESSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84876333761     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.229.163     Document Type: Article

References (36)

1. Agusti, A.G. (2005) Systemic effects of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc., 2, 367-370.
2. Anto, J.M., Vermeire, P., Vestbo, J. amp; Sunyer, J. (2001) Epidemiology of chronic obstructive pulmonary disease. Eur. Respir. J., 17, 982-994.
3. Bara, I., Ozier, A., Girodet, P.O., Carvalho, G., Cattiaux, J., Begueret, H., Thumerel, M., Ousova, O., Kolbeck, R., Coyle, A.J., Woods, J., Tunon de Lara, J.M., Marthan, R. & Berger, P. (2012) Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am. J. Respir. Crit. Care Med., 185, 715-722.
4. Barnes, P.J., Shapiro, S.D. & Pauwels, R.A. (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J., 22, 672-688.
5. Boot, R.G., van Achterberg, T.A., van Aken, B.E., Renkema, G.H., Jacobs, M.J., Aerts, J.M. & de Vries, C.J. (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol., 19, 687-694.
6. Donaldson, G.C., Seemungal, T.A., Patel, I.S., Bhowmik, A., Wilkinson, T.M., Hurst, J.R., Maccallum, P.K. & Wedzicha, J.A. (2005) Airway and systemic inflammation and decline in lung function in patients with COPD. Chest, 128, 1995-2004.
7. Fitzpatrick, S.F., Tambuwala, M.M., Bruning, U., Schaible, B., Scholz, C.C., Byrne, A., O'Connor, A., Gallagher, W.M., Lenihan, C.R., Garvey, J.F., Howell, K., Fallon, P.G., Cummins, E.P. & Taylor, C.T. (2011) An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J. Immunol., 186, 1091-1096.
8. Gan, W.Q., Man, S.F., Senthilselvan, A. & Sin, D.D. (2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 59, 574-580.
9. Garvey, J.F., Taylor, C.T. & McNicholas, W.T. (2009) Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur. Respir. J., 33, 1195-1205.
10. GOLD Committee. (2011) Global Strategy for the Diagnosis, Management, and Prevention of COPD. Available at: www. goldcopd.org/guidelines-gold-summary-2011.html.
11. Hauschka, P.V., Mann, K.G., Price, P. & Termine, J.D. (1986) Report of the Ad Hoc Committee on Nomenclature and Standards for Bone Proteins and Growth Factors. J. Bone Miner. Res., 1, 485-486.
12. Johansen, J.S., Bojesen, S.E., Tybjaerg-Hansen, A., Mylin, A.K., Price, P.A. & Nordestgaard, B.G. (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clin. Chem., 56, 1580-1591.
13. Johansen, J.S., Drivsholm, L., Price, P.A. & Christensen, I.J. (2004) High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer, 46, 333-340.
14. Johansen, J.S., Jensen, H.S. & Price, P.A. (1993) A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol., 32, 949-55.
15. Johansen, J.S., Milman, N., Hansen, M., Garbarsch, C., Price, P.A. & Graudal, N. (2005) Increased serum YKL-40 in patients with pulmonary sarcoidosis: a potential marker of disease activity? Respir. Med., 99, 396-402.
16. Johansen, J.S., Stoltenberg, M., Hansen, M., Florescu, A., Hørslev-Petersen, K., Lorenzen, I. & Price, P.A. (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relationto disease activity. Rheumatology, 38, 618-626.
17. Kent, B.D., Mitchell, P.D. & McNicholas, W.T. (2011) Hypoxemia in patients with COPD: cause, effects, and disease progression. Int. J. Chron. Obstruct. Pulmon. Dis., 6, 199-208.
18. Kwon, J.W., Kim, T.W., Cho, S.H., Min, K.U. & Park, H.W. (2011) Serum YKL-40 levels are correlated with symptom severity in patients with allergic rhinitis. Allergy, 66, 1252-1253.
19. Letuve, S., Kozhich, A., Arouche, N., Grandsaigne, M., Reed, J., Dombret, M.C., Kiener, P.A., Aubier, M., Coyle, A.J. & Pretolani, M. (2008) YKL-40 Is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J. Immunol., 181, 5167-5173.
20. Lin, C.H., Li, H.Y., Der Jiang, Y., Chang, T.J. & Chuang, L.M. (2012) Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in Individuals with type 2 diabetes. Clin. Endocrinol. [Epub ahead of print].
21. Nordenbaek, C., Johansen, J.S., Halberg, P., Wiik, A., Garbarsch, C., Ullman, S., Price, P.A. & Jacobsen, S. (2005) High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand. J. Rheumatol., 34, 293-297.
22. Nordenbaek, C., Johansen, J.S., Junker, P., Borregaard, N., Sørensen, O. & Price, P.A. (1999) YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J. Infect. Dis., 180, 1722-1726.
23. Rathcke, C.N. & Vestergaard, H. (2009) YKL-40 - an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc. Diabetol., 8, 61.
24. Rehli, M., Niller, H.H., Ammon, C., Langmann, S., Schwarzfischer, L., Andreesen, R. & Krause, S.W. (2003) Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem., 278, 44058-44067.
25. Renkema, G.H., Boot, R.G., Au, F.L., Donker-Koopman, W.E., Strijland, A., Muijsers, A.O., Hrebicek, M. & Aerts, J.M. (1998) Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem., 251, 504-509.
26. Roslind, A. & Johansen, J.S. (2009) YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol. Biol., 511, 159-184.
27. Ryan, S., Taylor, C.T. & McNicholas, W.T. (2009) Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome. Thorax, 64, 631-636.
28. Sakazaki, Y., Hoshino, T., Takei, S., Sawada, M., Oda, H., Takenaka, S., Imaoka, H., Matsunaga, K., Ota, T., Abe, Y., Miki, I., Fujimoto, K., Kawayama, T., Kato, S. & Aizawa, H. (2011) Overexpression of chitinase 3-like 1/YKL-40 in lungspecific IL-18-transgenic mice, smokers and COPD. PLoS One, 6, e24177.
29. Shuhui, L., Mok, Y.K. & Wong, W.S. (2009) Role of mammalian chitinases in asthma. Int. Arch. Allergy Immunol., 149, 369-377.
30. Takabatake, N., Nakamura, H., Abe, S., Inoue, S., Hino, T., Saito, H., Yuki, H., Kato, S. & Tomoike, H. (2000) The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 161, 1179-1184.
31. Tkacova, R., Ukropec, J., Skyba, P., Ukropcova, B., Pobeha, P., Kurdiova, T., Joppa, P., Klimes, I., Tkac, I. & Gasperikova, D. (2011) Increased adipose tissue expression of proinflammatory CD40, MKK4 and JNK in patients with very severe chronic obstructive pulmonary disease. Respiration, 81, 386-393.
32. Van Eeden, S.F. & Hogg, J.C. (2000) The response of human bone marrow to chronic cigarette smoking. Eur. Respir. J., 15, 915-921.
33. Volck, B., Johansen, J.S., Stoltenberg, M., Garbarsch, C., Price, P.A., Ostergaard, M., Ostergaard, K., Løvgreen-Nielsen, P., Sonne-Holm, S. & Lorenzen, I. (2001) Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage, 9, 203-214.
34. Volck, B., Price, P.A., Johansen, J.S., Sørensen, O., Benfield, T.L., Nielsen, H.J., Calafat, J. & Borregaard, N. (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians, 110, 351-360.
35. Vestbo, J., Hurd, S.S., Agusti, A.G., Jones, P.W., Vogelmeier, C., Anzueto, A., Barnes, P.J., Fabbri, L.M., Martinez, F.J., Nishimura, M., Stockley, R.A., Sin, D.D. & Rodriguez-Roisin, R. (2012) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am. J. Respir. Crit. Care Med., [Epub ahead of print].
36. Wagner, P.D. (2008) Possible mechanisms underlying the development of cachexia in COPD. Eur. Respir. J., 31, 492-501.